Ambrisentan and IgA Nephropathy: Does It Reduce Proteinuria and Is It Safe?

　　Can ambrisentan reduce proteinuria in IgA nephropathy?

　　Ambrisentan is an endothelin type A receptor antagonist.Its main labeled use is pulmonary arterial hypertension with WHO functional class II or III symptoms.

　　The endothelin pathway is involved in glomerular injury and proteinuria,so ambrisentan may be studied in IgA nephropathy.However,sharing a pathway does not mean the drug already has proven clinical benefit for this disease.

　　Clearer proteinuria-reduction evidence comes from atrasentan.The ALIGN trial showed atrasentan reduced urine protein-to-creatinine ratio in IgA nephropathy,with longer-term eGFR data reported.Atrasentan is not the same drug as ambrisentan,so its results should not be directly transferred to ambrisentan.

　　Why are endothelin receptor antagonists studied in IgA nephropathy?

　　Endothelin-1 may affect intraglomerular pressure,mesangial proliferation,podocyte injury,inflammation,and fibrosis.Blocking the ETA receptor is therefore a plausible way to reduce proteinuria and slow renal decline.

　　For this reason,endothelin receptor antagonists are being studied as non-immunosuppressive options in IgA nephropathy.Still,each agent differs in selectivity,dose,safety data,and approval status.Using ambrisentan in IgA nephropathy would usually mean off-label use or research settings,not standard self-treatment.

　　Should IgA nephropathy patients take ambrisentan on their own?

　　No.

　　Ambrisentan can cause fluid retention,peripheral edema,anemia,and fetal toxicity in pregnancy;liver monitoring is also required.Patients with existing edema,reduced renal function,cardiovascular disease,uncontrolled blood pressure,or complex medication use need careful assessment.

　　If a physician considers it,the decision should be based on kidney biopsy confirmation,proteinuria level,eGFR,blood pressure,potassium,liver function,concomitant drugs,and follow-up capacity.

　　Which indicators matter for proteinuria treatment?

　　A single dipstick result is not enough.Monitor:

　　24-hour proteinuria or urine protein-to-creatinine ratio

　　eGFR and serum creatinine trend

　　blood pressure

　　serum potassium and liver function

　　edema,weight change,and symptoms of heart failure

　　The goal is sustained proteinuria control and slower loss of kidney function,not just one temporary reduction.